UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 950
- Registration Number
- NCT00152386
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 66
- Registration Number
- NCT00150813
Facial Thermography Study of Levocetirizine Versus Cetirizine
Phase 4
Completed
- Conditions
- Anti-allergic Agents
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00150761
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
Phase 3
Completed
- Conditions
- Generalized Epilepsy
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 217
- Registration Number
- NCT00150748
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
Phase 3
Completed
- Conditions
- Generalized Epilepsy
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 580
- Registration Number
- NCT00150735
Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.
Phase 3
Completed
- Conditions
- Epilepsy, Tonic-clonic
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 250
- Registration Number
- NCT00150787
Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults
Phase 3
Completed
- Conditions
- Generalized Convulsive Epilepsy
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 116
- Registration Number
- NCT00150774
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 223
- Registration Number
- NCT00150709
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
Not Applicable
Completed
- Conditions
- Diabetic Gastroparesis
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00139893
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00139880
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath